BOSTON--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical data from its oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held in San Diego, CA. In addition, two trial-in-progress posters for Affini-T's Phase 1 clinical-stage programs targeting KRAS G12V, the company-sponsored AFNT-211 study and the Fred Hutchinson Cancer Center investigator-initiated AFNT-111 study, will be presented at the same conference.
Poster presentation details are as follows:
Title: Non-viral engineered T cell therapy specific for the hotspot mutation p53 R175H that integrates signal 1 (TCR), signal 2 (co-stimulation) and signal 3 (cytokine) and co-opts FasL-dependent apoptosis to achieve a coordinated antitumor CD4/8 T cell response
Session: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T
Abstract Number: 7242
Presenting Author: Gary Shapiro, Ph.D., VP Biology Discovery, Affini-T Therapeutics
Date/Time: Sunday, April 7, 2024, 1:30 PM - 5:00 PM
Title: AFNT-212: A TRAC-knocked-in KRAS G12D-specific TCR-T cell product enhanced with CD8αβ and a chimeric cytokine receptor for treatment of solid cancers
Session: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T
Abstract Number: 5973
Presenting Author: Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics
Date/Time: Sunday, April 7, 2024, 1:30 PM - 5:00 PM
Title: Identifying novel patient-derived T cell receptors targeting TP53 public neoantigens
Session: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T
Abstract Number: 441
Presenting Author: Michael V. Gormally, M.D., Ph.D., Fellow, Memorial Sloan Kettering Cancer Center
Date/Time: Sunday, April 7, 2024, 1:30 PM - 5:00 PM
Title: AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
Session: Phase I Clinical Trials in Progress 1
Abstract Number: CT076
Presenting Author: Dirk Nagorsen, M.D., Chief Medical Officer, Affini-T Therapeutics
Date/Time: Monday, April 8, 2024, 9:00 AM - 12:30 PM
Title: Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal, and non-small cell lung cancers with KRAS G12V mutations
Session: Phase I Clinical Trials in Progress 1
Abstract Number: CT082
Presenting Author: Aude G. Chapuis, M.D., Fred Hutchinson Cancer Center
Date/Time: Monday, April 8, 2024, 9:00 AM - 12:30 PM
About Affini-T Therapeutics
Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. For more information, visit affinittx.com and follow us on LinkedIn and X, formerly known as Twitter.
